miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart

Published: Nov 04, 2011

BOULDER, Colo.--(BUSINESS WIRE)--MiRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research demonstrates that microRNA-15 (miR-15) is upregulated in response to ischemic damage in two important model systems and contributes to cardiovascular disease by regulating heart muscle cell death following a heart attack. The research was conducted by miRagen scientists in collaboration with researchers at the University of Texas Southwestern Medical Center and University of Miami Miller School of Medicine.

Back to news